Full Press Release Details
PONTE VEDRA, Fla. , Aug. 14, 2024 — Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, will participate in the following upcoming conferences that will be available to investors by webcast.
At the Sidoti and Investor Summit conferences, management will also participate in one-on-one institutional investor meetings. To request a meeting with management, please contact your conference representative or the Company’s investor relations team at cvkd@lythampartners.com .
Sidoti Micro-cap Virtual Conference Cadrenal Chief Medical Officer, Dr. Douglas Losordo , will present highlights of the Company’s pipeline progress at the Sidoti Micro-cap Virtual Conference on Thursday, August 15, 2024 , at 2:30 p.m . ET. The webcast can be accessed by visiting the investor relations section of the Company’s website at https://www.cadrenal.com/investors/ or accessed here . A replay of the presentation will also be available via these sites.
Summer 2024 Investor Summit Cadrenal Chief Executive Officer, Quang Pham , will present an overview of the Company and its lead candidate tecarfarin at the Summer 2024 Investor Summit Virtual Conference on Tuesday, August 20, 2024 at 3 p.m . ET. The webcast can be accessed by visiting the investor relations section of the Company’s website at https://www.cadrenal.com/investors/ . A replay of the presentation will also be available online.
Emerging Growth Conference Cadrenal Chief Executive Officer, Quang Pham , will deliver an update presentation during the Emerging Growth Conference on Wednesday, August 21, 2024 , at 3:55 p.m . ET. The webcast can be accessed by visiting the investor relations section of the Company’s website at https://www.cadrenal.com/investors/ or accessed here . A replay of the presentation will also be available at these sites.
ABOUT CADRENAL THERAPEUTICS, INC. Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions. Tecarfarin has orphan drug designation for the prevention of thrombosis and thromboembolism in patients with ventricular assist devices. Tecarfarin also has orphan drug and fast-track designations from the FDA for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease and atrial fibrillation. Cadrenal is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in 11 human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com .
For more information, please contact: